{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T02:25:09Z","timestamp":1780971909952,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,15]]},"DOI":"10.7759\/cureus.12713","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T09:26:29Z","timestamp":1610702789000},"source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Fatty Liver Disease: The Present and the Future"],"prefix":"10.7759","author":[{"given":"Sruthi Priyavadhana","family":"Ramanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Wael F","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Sandi","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Sange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance","volume":"114","author":"Handberg A","year":"2016","unstructured":"Handberg A, Levin K, Hojlund K, et al.. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. 2016, 114:1169-1176."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1503519","article-title":"Cause pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl AM","year":"2017","unstructured":"Diehl AM, Day C. Cause pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017, 377:2063-2072. 10.1056\/NEJMra1503519","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes C","year":"2018","unstructured":"Estes C, Razavi H, Loomba R. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018, 67:123-133. 10.1002\/hep.29466","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2036.2007.03246.x","article-title":"GI epidemiology: nonalcoholic fatty liver disease","volume":"25","author":"Angulo P","year":"2007","unstructured":"Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007, 25:883-889.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman SL","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA Rinella M, Sanyal A.J. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018, 24:908-922. 10.1038\/s41591-018-0104-9","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1716333","article-title":"Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) -how are clinical trials affected?","volume":"1","author":"Michel M","year":"2020","unstructured":"Michel M, Schattenberg JM. Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) -how are clinical trials affected?. Expert Opin Investig Drugs. 2020, 1:5-10. 10.1080\/13543784.2020.1716333","journal-title":"Expert Opin Investig Drugs"},{"key":"ref7","article-title":"The patient perspectives on future therapeutic options in NASH and patient needs","volume":"6","author":"Cook N","year":"2019","unstructured":"Cook N, Geier A, Schmid A, et al.. The patient perspectives on future therapeutic options in NASH and patient needs. Front Med (Lausanne). 2019, 6:61-10.","journal-title":"Front Med (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.05.019","article-title":"Lipotoxicity in NASH","volume":"56","author":"Fuchs M","year":"2012","unstructured":"Fuchs M, Sanyal AJ. Lipotoxicity in NASH. J Hepatol. 2012, 56:291-293. 10.1016\/j.jhep.2011.05.019","journal-title":"J Hepatol"},{"key":"ref9","article-title":"Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity","volume":"16","author":"Park JS","year":"2020","unstructured":"Park JS, Lee DH, Lee YS, et al.. Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity. Autophagy. 2020, 16:86-105.","journal-title":"Autophagy"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1089\/ars.2010.3222","article-title":"Discovery of the negative regulator of Nrf2, Keap1: a historical overview","volume":"13","author":"Itoh K","year":"2010","unstructured":"Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal. 2010, 13:1665-1678.","journal-title":"Antioxid Redox Signal"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2443.2010.01473.x","article-title":"Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution","volume":"16","author":"Taguchi K","year":"2011","unstructured":"Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells. 2011, 16:123-140. 10.1111\/j.1365-2443.2010.01473.x","journal-title":"Genes Cells"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1152\/physrev.00003.2009","article-title":"Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease","volume":"90","author":"Glatz JF","year":"2010","unstructured":"Glatz JF, Luiken JJ, Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol Rev. 2010, 90:367-417.","journal-title":"Physiol Rev"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.2337\/db07-0907","article-title":"Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity","volume":"56","author":"Koonen DP","year":"2007","unstructured":"Koonen DP, Jacobs RL, Febbraio M, et al.. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007, 56:2863-2871.","journal-title":"Diabetes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M090969","article-title":"CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway","volume":"60","author":"Li Y","year":"2019","unstructured":"Li Y, Yang P, Zhao L, et al.. CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway. J Lipid Res. 2019, 60:844-855. 10.1194\/jlr.M090969","journal-title":"J Lipid Res"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2005.08.070","article-title":"Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice","volume":"336","author":"Inoue M","year":"2005","unstructured":"Inoue M, Ohtake T, Motomura W. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun. 2005, 336:215-222.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.626135","article-title":"Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance","volume":"114","author":"Handberg A","year":"2006","unstructured":"Handberg A, Levin K, Hojlund K, Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation. 2006, 114:1169-1176. 10.1161\/CIRCULATIONAHA.106.626135","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada P","year":"2020","unstructured":"Rada P, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Garc\u00eda-Monz\u00f3n C, Valverde AM. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?. Cell Death Dis. 2020, 11:802.","journal-title":"Cell Death Dis"},{"key":"ref18","article-title":"Deficiency of CD147 attenuated non-alcoholic steatohepatitis progression in an NLRP3-dependent manner","volume":"8","author":"Zhang T","year":"2020","unstructured":"Zhang T, Li H, Wang K, Xu B, Chen ZN, Bian H. Deficiency of CD147 attenuated non-alcoholic steatohepatitis progression in an NLRP3-dependent manner. Front Cell Dev Biol. 2020, 8:784.","journal-title":"Front Cell Dev Biol"},{"key":"ref19","article-title":"L-selectin\/CD62L is a key driver of non-alcoholic steatohepatitis in mice and men","volume":"9","author":"Drescher HK","year":"2020","unstructured":"Drescher HK, Schippers A, Rosenhain S, et al.. L-selectin\/CD62L is a key driver of non-alcoholic steatohepatitis in mice and men. 2020, 9:1106."},{"key":"ref20","article-title":"Hepatoprotective and anti-oxidative effects of total flavonoids from Qu Zhi Qiao (fruit of Citrus Paradisi cv. Changshanhuyou) on nonalcoholic steatohepatitis in vivo and in vitro through Nrf2-ARE signaling pathway","volume":"11","author":"Shi Z","year":"2020","unstructured":"Shi Z, Li T, Liu Y, et al.. Hepatoprotective and anti-oxidative effects of total flavonoids from Qu Zhi Qiao (fruit of Citrus Paradisi cv. Changshanhuyou) on nonalcoholic steatohepatitis in vivo and in vitro through Nrf2-ARE signaling pathway. Front Pharmacol. 2020, 11:483.","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061346","article-title":"Deletion of perilipin 5 protects against hepatic injury in nonalcoholic fatty liver disease via missing inflammasome activation","volume":"9","author":"Asimakopoulou A","year":"2020","unstructured":"Asimakopoulou A, Engel KM, Gassler N, et al.. Deletion of perilipin 5 protects against hepatic injury in nonalcoholic fatty liver disease via missing inflammasome activation. Cells. 2020, 9:1346.","journal-title":"Cells"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.201900576","article-title":"Dual farnesoid x receptor\/soluble epoxide hydrolase modulators derived from zafirlukast","volume":"15","author":"Schierle S","year":"2020","unstructured":"Schierle S, Helmst\u00e4dter M, Schmidt J, et al.. Dual farnesoid x receptor\/soluble epoxide hydrolase modulators derived from zafirlukast. ChemMedChem. 2020, 15:50-67.","journal-title":"ChemMedChem"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-57784-3","article-title":"Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice","volume":"10","author":"Nishikawa T","year":"2020","unstructured":"Nishikawa T, Nagata N, Shimakami T, et al.. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep. 2020, 10:815.","journal-title":"Sci Rep"},{"key":"ref24","article-title":"The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar DP","year":"2020","unstructured":"Kumar DP, Caffrey R, Marioneaux J, et al.. The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. Sci Rep. 2020, 10:9330.","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima T","year":"2016","unstructured":"Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr. 2016, 8:45.","journal-title":"Diabetol Metab Syndr"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.2147\/DMSO.S184767","article-title":"Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis","volume":"11","author":"Seko Y","year":"2018","unstructured":"Seko Y, Nishikawa T, Umemura A, et al.. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab Syndr Obes. 2018, 11:835-843.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba K","year":"2018","unstructured":"Shiba K, Tsuchiya K, Komiya C, et al.. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep. 2018, 8:2362. 10.1038\/s41598-018-19658-7","journal-title":"Sci Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57935-6","article-title":"Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects","volume":"10","author":"Kawakubo M","year":"2020","unstructured":"Kawakubo M, Tanaka M, Ochi K, et al.. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. Sci Rep. 2020, 10:983. 10.1038\/s41598-020-57935-6","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.09.025","article-title":"Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"137","author":"Bifari F","year":"2018","unstructured":"Bifari F, Manfrini R, Dei CM, et al.. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacol Res. 2018, 137:219-229. 10.1016\/j.phrs.2018.09.025","journal-title":"Pharmacol Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-015-6592-7","article-title":"Preservation of glucagon-like peptide-1 level attenuates angiotensin iiinduced tissue fibrosis by altering AT1\/AT2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart","volume":"29","author":"Zhang L","year":"2015","unstructured":"Zhang L, Pang X, Bai F, et al.. Preservation of glucagon-like peptide-1 level attenuates angiotensin iiinduced tissue fibrosis by altering AT1\/AT2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart. Cardiovasc Drugs Ther. 2015, 29:243-255. 10.1007\/s10557-015-6592-7","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00432","article-title":"Liraglutide attenuates non-alcoholic fatty liver disease in mice by regulating the local renin-angiotensin system","volume":"11","author":"Yang M","year":"2020","unstructured":"Yang M, Ma X, Xuan X, Deng H, Chen Q, Yuan L. Liraglutide attenuates non-alcoholic fatty liver disease in mice by regulating the local renin-angiotensin system. Front Pharmacol. 2020, 11:432. 10.3389\/fphar.2020.00432","journal-title":"Front Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184694","article-title":"Differential impact of the dual CCR2\/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury","volume":"12","author":"Puengel T","year":"2017","unstructured":"Puengel T, Krenkel O, Kohlhepp M, Lefebvre E, Luedde T, Trautwein C, Tacke F. Differential impact of the dual CCR2\/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury. PLoS One. 2017, 12:0184694. 10.1371\/journal.pone.0184694","journal-title":"PLoS One"},{"key":"ref33","article-title":"Evaluating the therapeutic potential of cenicriviroc in the treatment of nonalcoholic steatohepatitis with fibrosis: a brief report on emerging data","volume":"12","author":"Diaz Soto MP","year":"2020","unstructured":"Diaz Soto MP, Lim JK. Evaluating the therapeutic potential of cenicriviroc in the treatment of nonalcoholic steatohepatitis with fibrosis: a brief report on emerging data. Hepat Med. 2020, 12:115-123.","journal-title":"Hepat Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-018-0841-9","article-title":"The genetic backgrounds in nonalcoholic fatty liver disease","volume":"11","author":"Seko Y","year":"2018","unstructured":"Seko Y, Yamaguchi K, Itoh Y. The genetic backgrounds in nonalcoholic fatty liver disease. Clin J Gastroenterol. 2018, 11:97-102. 10.1007\/s12328-018-0841-9","journal-title":"Clin J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2019.04.006","article-title":"MBOAT7 is anchored to endomembranes by six transmembrane domains","volume":"206","author":"Caddeo A","year":"2019","unstructured":"Caddeo A, Jamialahmadi O, Solinas G, Pujia A, Mancina RM, Pingitore P, Romeo S. MBOAT7 is anchored to endomembranes by six transmembrane domains. J Struct Biol. 2019, 206:349-360. 10.1016\/j.jsb.2019.04.006","journal-title":"J Struct Biol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.045","article-title":"The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans","volume":"65","author":"Luukkonen PK","year":"2016","unstructured":"Luukkonen PK, Zhou Y, Hy\u00f6tyl\u00e4inen T, et al.. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol. 2016, 65:1263-1265. 10.1016\/j.jhep.2016.07.045","journal-title":"J Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320853","article-title":"Loss of hepatic Mboat7 leads to liver fibrosis. [Epub ahead of print]","author":"Thangapandi VR","year":"2020","unstructured":"Thangapandi VR, Knittelfelder O, Brosch M, et al.. Loss of hepatic Mboat7 leads to liver fibrosis. [Epub ahead of print]. Gut. 2020, 10.1136\/gutjnl-2020-320853","journal-title":"Gut"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00189-13","article-title":"MCJ\/DnaJC15, an endogenous mitochondrial repressor of the respiratory chain that controls metabolic alterations","volume":"33","author":"Hatle KM","year":"2013","unstructured":"Hatle KM, Gummadidala P, Navasa N, et al.. MCJ\/DnaJC15, an endogenous mitochondrial repressor of the respiratory chain that controls metabolic alterations. Mol Cell Biol. 2013, 33:2302-2314. 10.1128\/MCB.00189-13","journal-title":"Mol Cell Biol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.626135","article-title":"Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation","volume":"11","author":"Barbier-Torres L","year":"2020","unstructured":"Barbier-Torres L, Fortner KA, Iruzubieta P, et al.. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. Nat Commun. 2020, 11:3360. 10.1161\/CIRCULATIONAHA.106.626135","journal-title":"Nat Commun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/46896-treatment-of-fatty-liver-disease-the-present-and-the-future","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:29Z","timestamp":1707506909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/46896-treatment-of-fatty-liver-disease-the-present-and-the-future"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.12713","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,15]]}}}